TICKERNERD
Menu
PLURPLURHealthcare · Biotechnology

PLUR Stock Forecast: Pluri, Inc. Price Predictions for 2026-2027

Last close, 13 Oct 2026
$0.94
−3.09% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 14 of 100 as at 13 Oct 2026 — in the weakest quartile.

Market cap
$11.8M
Ticker Nerd rank
14 / 100
Median analyst target
—
Analysts covering
1
Revenue$335K−15.8% y/y
Operating income−$5.5M
Net income−$6.2M
Free cash flow−$4.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.1%
1M
−20.3%
YTD
−68.6%
1Y
−79.0%
From 52W high
−79.2%
From 52W low
0.0%
$0.94
$4.52
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PLUR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Pluri, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 13 Oct 2026
14 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
91
Accruals
84
Growth
45
Volatility
32
Revisions
25
Issuance
14
Value
8
Quality
7
Momentum
6

Size (91): Smaller than most of the companies we track.

Momentum (6): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PLUR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PLUR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00Jan 26Apr 26Jul 26Oct 26PLUR

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
2 June 2025Alliance Global PartnersInitiatesBuy$12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PLUR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

PLUR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 13 Oct 2026, Pluri, Inc. returned −79.0% against +18.6% for the S&P 500, dividends included.

PLUR vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26PLURS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PLUR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Pluri, Inc. (PLUR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.3×

Cheaper than 80% of US stocks

Price / sales
11.5×

Cheaper than 13% of US stocks

Price / book
−1.0×

Cheaper than 94% of US stocks

EV / EBITDA
−1.8×

Cheaper than 72% of US stocks

Growth & margins
Revenue growth (YoY)
−15.8%

Higher than 13% of US stocks

Earnings growth (YoY)
—
Gross margin
58.5%

Higher than 72% of US stocks

Operating margin
−1655.5%

Higher than 4% of US stocks

Net margin
44.6%

Higher than 95% of US stocks

Returns & dividend
Return on equity
136.6%

Higher than 97% of US stocks

Return on assets
−49.0%

Higher than 8% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Pluri, Inc. (PLUR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Pluri, Inc. has a market value of $11.8M and an enterprise value of $44.5M.

  • Revenue in the twelve months to 30 June 2026: $1.0M. The latest quarter shrank 15.8% year on year.

  • Net income over the same four quarters: −$25.4M, a −2496.9% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$20.2M.

  • Shares outstanding: 10.8M.

  • Trailing P/E: −0.3×; forward P/E: −0.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Pluri, Inc. employs 92 people — $11K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 12 Oct 2026

Data provided by Twelve Data

Peers

PLUR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PLURPluri, Inc.$11.8M
14
INTSIntensity Therapeutics, Inc.$11.6M
30
INABIN8bio, Inc.$11.5M
56
TPSTTempest Therapeutics, Inc.$11.5M
45
PASGPassage Bio, Inc.$11.7M
44
AEONAEON Biopharma, Inc.$11.5M
51
ACTUActuate Therapeutics, Inc.$11.2M
34

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Pluri, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PLUR news & analysis

Ever After Foods and Roslin Technologies Achieve Major Leap in Cultivated Meat Productivity

GlobeNewsWire · 13 Oct 2026positive

Ever After Foods and Roslin Technologies announced results from their joint cultivated meat program, combining Roslin’s cell platform with Ever After Foods’ Edible Packed Bed technology. They reported gains in protein and biomass productivity while producing structured tissue in a scalable, food-grade process.

Why it matters — The announcement describes productivity gains involving Ever After Foods, which may be relevant to PLUR watchers tracking cultivated-meat industry developments.

Pluri Announces Pricing of $3.3 Million Registered Direct Offering and Concurrent Private Placement with a Single Healthcare Focused Institutional Investor

GlobeNewsWire · 27 Aug 2026neutral

Pluri announced a securities purchase agreement with a single healthcare-focused institutional investor for a registered direct offering of 2,228,940 common shares at $1.50 per share, expected to generate approximately $3.3 million in gross proceeds before fees and expenses.

Why it matters — This offering provides Pluri with fresh capital via a healthcare-focused institutional investor, which PLUR watchers would track for the company's funding and dilution impact.

Plurilock Security Inc. (PLUR:CA) Discusses Corporate Update and Growth Strategy in Defense Contracting Portfolio Transcript

Seeking Alpha · 20 Aug 2026neutral

Plurilock Security Inc. presented a corporate update and discussed its growth strategy within its defense contracting portfolio, as covered in a Seeking Alpha transcript of the discussion.

Why it matters — PLUR watchers would be interested because the company outlined its approach and direction for its defense contracting business, which is a key part of its portfolio.

Pluri's Ever After Foods Expands Cultivated-Protein Platform Through Fishway Acquisition and Strategic Investment

GlobeNewsWire · 17 Aug 2026positive

Pluri's majority-owned food-tech company, Ever After Foods, has expanded its cultivated-protein platform through the acquisition of Fishway and a strategic investment. This adds aquatic cell biology, animal-component-free media capabilities, and a European scientific presence to the company.

Why it matters — For Pluri watchers, this expansion broadens Ever After Foods' cultivated-protein capabilities and geographic scientific reach under the company's majority ownership.

Pluri Advances Commercial Expansion Through Its Subsidiary Cellav, Completing Regulatory Registration in the UK

GlobeNewsWire · 28 July 2026positive

Pluri's consumer-health subsidiary, Cellav, completed regulatory registration in the UK for its regenerative aesthetics product Regenativo+, paving the way for a commercial launch in a market estimated at roughly $900 million annually.

Why it matters — This milestone advances Pluri's commercialization strategy by opening a significant new market and laying the groundwork for broader international expansion of its regenerative aesthetics portfolio.

FAQ

Frequently asked questions about PLUR stock

Is PLUR stock a buy right now?

Of the 1 analysts covering Pluri, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Pluri, Inc. 14 out of 100 across roughly 4,600 US stocks as at 13 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PLUR?

As at 13 Oct 2026, Pluri, Inc. ranks 14 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (91 of 100).

What is the PLUR stock forecast for 2030?

No analyst covering Pluri, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PLUR are extrapolating price history, which says nothing about the business.

How has PLUR stock performed over the past year?

Pluri, Inc. returned -79.0% over the 12 months to 13 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Pluri, Inc. do?

Pluri Inc. is a biotechnology company focused on the research, development, manufacturing, and commercialization of cell-based products and related technologies.

What is the latest news on PLUR?

The most recent item we track (GlobeNewsWire, 13 Oct 2026): "Ever After Foods and Roslin Technologies Achieve Major Leap in Cultivated Meat Productivity". Ever After Foods and Roslin Technologies announced results from their joint cultivated meat program, combining Roslin’s cell platform with Ever After Foods’ Edible Packed Bed technology. They reported gains in protein and biomass productivity while producing structured tissue in a scalable, food-grade process.

Company

About Pluri, Inc.

Pluri Inc. is a biotechnology company focused on the research, development, manufacturing, and commercialization of cell-based products and related technologies. The company uses its proprietary three-dimensional cell expansion platform to support scalable cell production for applications across regenerative medicine, immunotherapy, food technology, and agricultural technology. Its current business areas include cell therapeutics, cultivated food solutions, and contract development and manufacturing services, reflecting a diversified platform built around advanced cell engineering. Pluri Inc. serves markets that rely on biological innovation to address medical, industrial, and sustainability challenges, positioning itself as a provider of cell-based solutions for both therapeutic and non-therapeutic uses. Headquartered in Haifa, Israel, Pluri Inc. operates as a clinical-stage biotechnology company with a focus on translating cell technology into practical commercial products and services.

CEO Mr. Yaacov Yanay · 92 employees · Israel · https://www.pluri-biotech.com